LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC.
Liu D, Liu H, Gan J, Zeng S, Zhong F, Zhang B, Zhang Z, Zhang S, Jiang L, Wang G, Chen Y, Kong FS, Fang W, Wang L.
Liu D, et al. Among authors: zhang b, zhang s, zhang z.
Front Pharmacol. 2022 Jun 23;13:918317. doi: 10.3389/fphar.2022.918317. eCollection 2022.
Front Pharmacol. 2022.
PMID: 35814257
Free PMC article.